Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lumos Pharma Inc
(NQ:
LUMO
)
4.300
-0.040 (-0.92%)
Streaming Delayed Price
Updated: 11:30 AM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
26,083
Open
4.320
Bid (Size)
4.300 (455)
Ask (Size)
4.330 (56)
Prev. Close
4.340
Today's Range
4.300 - 4.410
52wk Range
1.370 - 4.576
Shares Outstanding
8,357,391
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
October 30, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Analyst Expectations For Lumos Pharma's Future
October 24, 2024
Via
Benzinga
Performance
YTD
+33.54%
+33.54%
1 Month
+11.11%
+11.11%
3 Month
+131.18%
+131.18%
6 Month
+42.38%
+42.38%
1 Year
+16.22%
+16.22%
More News
Read More
INVESTIGATION ALERT: Halper Sadeh LLC Continues to Investigate MMLP, FSHP, ICCH, and LUMO on Behalf of Shareholders
October 24, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
October 23, 2024
From
Halper Sadeh LLC
Via
Business Wire
Lumos Pharma: Q4 Earnings Insights
March 07, 2024
Via
Benzinga
Earnings Preview: Lumos Pharma
March 06, 2024
Via
Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
October 23, 2024
From
Ademi LLP
Via
Business Wire
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
October 23, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
September 25, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
September 05, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 15, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
August 01, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
July 23, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
June 04, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
May 14, 2024
Via
InvestorPlace
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
May 09, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
April 18, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
March 25, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
March 20, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
March 07, 2024
Via
InvestorPlace
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
March 07, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
February 26, 2024
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.